This article is more than 5 years old. Information may no longer be current.
imaware to match $10K in donations for Rheumatoid Awareness Day
Click Here to Manage Email Alerts
In recognition of Rheumatoid Awareness Day on Feb. 2, at-home health testing platform imaware has announced it will match all donations to the Rheumatoid Patient Foundation up to $10,000 through Feb. 12, according to a press release.
"Rheumatoid Patient Foundation’s mission is to improve the lives of people with rheumatoid disease,” Kelly O’Neill Young, founder and president of the Rheumatoid Patient Foundation, said in the release. “With the medications available today, nothing improves outcomes as much as early diagnosis and treatment. The imaware test has the potential to help millions of people have more successful treatment and a better life."
Rheumatoid Arthritis Day was established in 2013 by the nonprofit Rheumatoid Patient Foundation with the aim of addressing the lack of public understanding of rheumatoid arthritis. The group, founded in 2011, strives to improve the lives of patients with rheumatoid diseases by advocating for expanded education, awareness and patient-centered research.
Developed by the health care company Microdrop, imaware is an at-home blood test that allows patients to test for either rheumatoid arthritis or celiac disease.
“We believe that the imaware at-home rheumatoid arthritis test will help reduce the number of undiagnosed people with RA,” Jani Tuomi, co-founder of imaware, said in the release. “With a partner like the Rheumatoid Patient Foundation, we will be able to better engage with the patient community to educate, screen and ultimately help patients engage their doctors sooner for diagnosis.”
In honor of Rheumatoid Awareness Day, and to help spread information and education regarding the chronic illness, Healio Rheumatology has compiled our recent coverage of the latest in rheumatoid arthritis news and findings.
Direct-to-consumer genetic testing not ready for prime time in rheumatology
Recent approvals for 23andMe have experts speculating whether such technology could be approved to predict risk for rheumatic conditions. Read More
RA risk increased up to fivefold among patients with high CCP levels
Among patients who are cyclic citrullinated peptide antibody positive, the risk for rheumatoid arthritis significantly increases as the level of antibodies rise, according to data published in Arthritis Care & Research. Read More
Single-infusion rituximab slows RA development in at-risk patients
A single 1,000-mg infusion of rituximab significantly slows the development of arthritis among patients at risk for rheumatoid arthritis, according to recent findings in the Annals of the Rheumatic Diseases. Read More
Infection risk with abatacept lower than TNF inhibitors in RA
Patients with rheumatoid arthritis who are treated with abatacept as a first- or second-line biologic treatment have a lower risk for hospitalized infection compared with those treated with TNF inhibitors, noted a recent report in Arthritis Care & Research. Read More
Calprotectin levels predicts relapse in patients with RA, PsA treated with TNF inhibitors
Baseline calprotectin serum levels independently predict disease relapse in patients with rheumatoid arthritis and psoriatic arthritis who have achieved remission or low disease activity, according to findings published in Arthritis Research & Therapy. Read More